Successful Completion of Phase I Clinical Study of Taphalgin

15.04.2020

We are pleased to announce the successful completion of the Phase I clinical trial for Taphalgin, our novel solution for subcutaneous injection. This open-label, non-randomized study focused on evaluating the safety, tolerability, and pharmacokinetics of Taphalgin in healthy volunteers. The trial began on March 22, 2019, and demonstrated promising results. This marks a significant milestone in our journey to bring more effective pain relief solutions to patients worldwide.

Successful Completion of Phase I Clinical Study of Taphalgin

About

Recent news

Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

Сontacts

©2016-2023 PVP LABS PTE. LTD